NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 862.7 DKK | -0.99% |
|
-0.76% | +23.58% |
| Apr. 18 | India's Biocon developing its own version of Wegovy, clinical trial likely next year | RE |
| Apr. 15 | More than 250 websites selling fake weight-loss drugs reported by anti-counterfeit firm | RE |
| Sales 2024 * | 287B 40.99B | Sales 2025 * | 346B 49.31B | Capitalization | 3,849B 549B |
|---|---|---|---|---|---|
| Net income 2024 * | 104B 14.78B | Net income 2025 * | 125B 17.85B | EV / Sales 2024 * | 13.5 x |
| Net Debt 2024 * | 26.72B 3.81B | Net Debt 2025 * | 3.78B 539M | EV / Sales 2025 * | 11.1 x |
| P/E ratio 2024 * |
37.3
x | P/E ratio 2025 * |
30.7
x | Employees | 63,845 |
| Yield 2024 * |
1.39% | Yield 2025 * |
1.67% | Free-Float | 70.47% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novo Nordisk A/S
More press releases
More news
| 1 day | -0.99% | ||
| 1 week | -0.76% | ||
| Current month | -2.11% | ||
| 1 month | -5.63% | ||
| 3 months | +17.81% | ||
| 6 months | +21.03% | ||
| Current year | +23.58% |
1 week
854.70
888.00
1 month
845.10903.90
Current year
688.80932.00
1 year
504.40932.00
3 years
224.33932.00
5 years
155.08932.00
10 years
109.10932.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 90-12-31 | |
| Director of Finance/CFO | 53 | 98-12-31 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 15-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 63 | 15-03-18 |
Helge Lund
CHM | Chairman | 61 | 17-03-22 |
Martin MacKay
BRD | Director/Board Member | 68 | 18-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 21.31% | 192 M€ | +11.42% | ||
| 10.45% | 5 M€ | +5.20% | ||
| 5.40% | 18 M€ | +2.91% | - | |
| 4.67% | 88 M€ | +10.37% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 862.7 | -0.99% | 2,297,378 |
| 24-04-17 | 871.3 | +0.44% | 1,469,864 |
| 24-04-16 | 867.5 | -1.33% | 1,728,440 |
| 24-04-15 | 879.2 | -0.09% | 1,814,804 |
| 24-04-12 | 880 | +1.23% | 2,064,983 |
Delayed Quote Nasdaq Copenhagen, April 18, 2024 at 10:59 am EDT
More quotes
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
862.7
DKK
Average target price
904.2
DKK
Spread / Average Target
+4.81%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.58% | 554B | |
| +27.97% | 676B | |
| -7.02% | 349B | |
| +14.85% | 318B | |
| +6.25% | 291B | |
| +2.96% | 210B | |
| -0.41% | 204B | |
| -10.02% | 194B | |
| -11.81% | 144B | |
| -8.80% | 142B |
- Stock Market
- Equities
- NOVO B Stock
